Galapagos Awarded Grant to Accelerate Drug Discovery
News Feb 11, 2009
Galapagos NV has announced that it has been awarded a €837,000 grant from the Flanders government through the Institute for the Promotion of Innovation by Science and Technology (IWT). Galapagos will elucidate the structure of novel drug targets and related small molecules in its bone & joint disease portfolio.
The two-year project "Drug discovery for bone and joint protection: structural biology for novel targets and their inhibitors" focuses on Galapagos' novel drug targets and the candidate drugs that bind to these targets. This information will help Galapagos to design potent and selective drugs and thus potentially improve their efficacy to treat bone and joint diseases. Galapagos will collaborate on this project with the renowned Structural Biology Brussels group at the Flanders Institute for Biotechnology (VIB).
"This grant gives us an opportunity to collaborate with the VIB's top structural biology group, thereby adding to our drug discovery capabilities," said Graham Dixon, SVP Drug Discovery for Galapagos.
"Through this research we aim to progress our understanding of these novel drug targets and accelerate the development of candidate drugs for bone & joint diseases."
New Chemical Synthesis Process: Synergy of Two Catalysts in One FlaskNews
Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.READ MORE
Synthesis of Drug-Like Molecules Simplified Using New Cross-Coupling MethodNews
Researchers have designed a new molecule-building method. The technique, described recently in the journal Science, paves the way toward other new chemical reactions and facilitates the synthesis of pharmaceutically-relevant molecules.READ MORE
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
Comments | 0 ADD COMMENT
Highly Potent Active Pharmaceutical Ingredients (HPAPI)
May 21 - May 22, 2018